Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4617537 | 0.94 | HTR6 (0.42) | HTR6DRD2CA2DRD4DRD3 | |
| SCHEMBL4636515 | 0.91 | DRD2 (0.49) | HTR6DRD2ALDH1A1MEN1KMT2A | |
| SCHEMBL4617179 | 0.91 | HTT (0.45) | HTR6DRD2CA2ADRA1AALDH1A1 | |
| SCHEMBL4617544 | 0.88 | DRD2 (0.48) | HTR6DRD2CA2ADRA1AALDH1A1 | |
| SCHEMBL4617526 | 0.86 | DRD2 (0.43) | HTR6DRD2ADRA1AMEN1KMT2A | |
| SCHEMBL4617689 | 0.86 | DRD2 (0.44) | HTR6DRD2ADRA1A | |
| SCHEMBL5321325 | 0.85 | DRD2 (0.42) | HTR6DRD2ADRA1AALDH1A1MEN1 | |
| SCHEMBL4616556 | 0.79 | ACHE (0.42) | DRD2ADRA1AALDH1A1MEN1KMT2A | |
| SCHEMBL27698157 | 0.77 | DRD2 (0.46) | HTR6DRD2ALDH1A1MEN1KMT2A | |
| SCHEMBL27679086 | 0.77 | HTT (0.44) | HTR6DRD2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139555-A1 | Arylthiobenzylpiperidine Derivatives | H. LUNDBECK A/S (DK) | 2008-06-12 | — | — | US | disclosed |
| US-7329656-B2 | Arylthiobenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2008-02-12 | — | — | US | disclosed |
| EP-1799223-A4 | ARYLTHIOBENZYLPIPERIDINE DERIVATES | LUNDBECK & CO AS H (DK) | 2008-01-23 | — | — | EP | disclosed |
| EP-1799223-A2 | ARYLTHIOBENZYLPIPERIDINE DERIVATES | H.Lundbeck A/S (DK) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006041635-A2 | ARYLTHIOBENZYLPIPERIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | H. LUNDBECK A/S | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | MCHR1, MTNR1A, MTNR1B | HTR6 25/4885DRD2 156/4885CA2 3665/4885 |
| US-20080139555-A1 | Arylthiobenzylpiperidine Derivatives | MCHR1, MC4R, MCHR2 | HTR6 25/4885DRD2 210/4885CA2 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.